The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. We perform more than 200 stem cell transplants a year. MSK is an international leader in the development of immunotherapy for the treatment of cancer. Chemotherapy kills the rapidly dividing cancer cells throughout the body. In a few cases, if the initial cancer is very small and can be removed during a biopsy , no further treatment may be needed. These varieties can be treated with much lower doses of radiation on smaller areas of the body than in the past. CAR T cell therapy is another potentially lifesaving option that could now be offered if you are not a candidate for stem cell transplantation, or if your disease relapses after a stem cell transplant. Our lymphoma experts are among the few teams around the world who have deciphered the basic science behind lymphoma development, patented lymphoma drugs, and directed national and international clinical trials leading to the domestic and international approval of new therapies. Because of the expertise of MSK’s transplant team, patients often have excellent results with both autologous (using the patient’s own cells) and allogeneic (cells from a donor) stem cell transplantation. Memorial Sloan Kettering is one of only a select few institutions equipped to administer CAR T cell therapy safely. This means your doctor will watch for any signs of change in your regular physical exams, blood tests, and imaging studies. Ready to Fight, but My Doctor Says to Wait: Watchful Waiting after a Lymphoma Diagnosis. Immunotherapy for Non-Hodgkin Lymphoma The most common side effects of treatment with Poteligeo included rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain and upper respiratory tract infection. Serious warnings of treatment with Poteligeo include the risk of dermatologic toxicity, infusion reactions, infections, autoimmune problems (a condition where the immune cells in the body attack other cells or organs in the body), and complications of stem cell transplantation that uses donor stem cells (allogeneic) after treatment with the drug. Explore how MSK scientists and clinicians are using an immunotherapy called chimeric antigen receptor (CAR) T cell therapy to beat cancer. These new treatments can often be more effective and less toxic than traditional chemotherapy. At MSK, we have many clinical trials with biologically targeted drugs to improve treatment options for people with non-Hodgkin lymphoma. “Mycosis fungoides and Sézary syndrome are rare, hard-to-treat types of non-Hodgkin lymphoma and this approval fills an unmet medical need for these patients,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.